RCUS
Income statement / Annual
Last year (2023), Arcus Biosciences, Inc.'s total revenue was $117.00 M,
an increase of 4.46% from the previous year.
In 2023, Arcus Biosciences, Inc.'s net income was -$307.00 M.
See Arcus Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$117.00 M
|
$112.00 M
|
$382.88 M
|
$77.52 M
|
$15.00 M
|
$8.35 M
|
$1.41 M
|
$0.00
|
| Cost of Revenue |
$340.00 M |
$14.00 M |
$7.06 M |
$159.00 M |
$78.48 M |
$49.65 M |
$2.61 M |
$1.31 M |
| Gross Profit |
-$223.00 M |
$98.00 M |
$375.83 M |
-$81.48 M |
-$63.48 M |
-$41.29 M |
-$1.20 M |
-$1.31 M |
| Gross Profit Ratio |
-1.91 |
0.88 |
0.98 |
-1.05 |
-4.23 |
-4.94 |
-0.85 |
0 |
| Research and Development
Expenses |
$340.00 M
|
$288.00 M
|
$256.35 M
|
$159.35 M
|
$78.48 M
|
$49.65 M
|
$47.22 M
|
$14.25 M
|
| General & Administrative
Expenses |
$117.00 M
|
$104.00 M
|
$72.29 M
|
$42.40 M
|
$25.23 M
|
$13.57 M
|
$7.64 M
|
$3.94 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$117.00 M
|
$104.00 M
|
$72.29 M
|
$42.40 M
|
$25.23 M
|
$13.57 M
|
$7.64 M
|
$3.94 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$457.00 M |
$392.00 M |
$328.63 M |
$201.75 M |
$103.71 M |
$63.21 M |
$54.85 M |
$18.18 M |
| Cost And Expenses |
$457.00 M |
$392.00 M |
$328.63 M |
$201.75 M |
$103.71 M |
$63.21 M |
$54.85 M |
$18.18 M |
| Interest Income |
$41.00 M |
$16.00 M |
$657,000.00 |
$1.38 M |
$5.20 M |
$4.92 M |
$359,000.00 |
$212,000.00 |
| Interest Expense |
$2.00 M |
$2.00 M |
$260,000.00 |
$0.00 |
$0.00 |
$4.92 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$8.00 M
|
$14.00 M
|
$7.06 M
|
$4.39 M
|
$3.58 M
|
$3.66 M
|
$2.61 M
|
$1.31 M
|
| EBITDA |
-$283.00 M
|
-$250.00 M
|
$61.96 M
|
-$118.47 M
|
-$81.13 M
|
-$51.20 M
|
-$50.83 M
|
-$16.87 M
|
| EBITDA Ratio |
-2.42 |
-2.36 |
0.14 |
-1.61 |
-5.91 |
-6.71 |
-35.97 |
0 |
| Operating Income Ratio
|
-2.91
|
-2.5
|
0.14
|
-1.6
|
-5.91
|
-6.57
|
-37.82
|
0
|
| Total Other
Income/Expenses Net |
$39.00 M
|
$14.00 M
|
$397,000.00
|
$1.38 M
|
$4.00 M
|
$5.27 M
|
$359,000.00
|
$212,000.00
|
| Income Before Tax |
-$301.00 M |
-$266.00 M |
$54.65 M |
-$122.86 M |
-$84.71 M |
-$49.59 M |
-$53.08 M |
-$17.97 M |
| Income Before Tax Ratio
|
-2.57
|
-2.38
|
0.14
|
-1.58
|
-5.65
|
-5.94
|
-37.57
|
0
|
| Income Tax Expense |
$6.00 M |
$1.00 M |
$1.82 M |
-$6.18 M |
-$8.78 M |
$5.27 M |
$0.00 |
$0.00 |
| Net Income |
-$307.00 M |
-$267.00 M |
$53.00 M |
-$116.68 M |
-$75.93 M |
-$49.59 M |
-$53.08 M |
-$17.97 M |
| Net Income Ratio |
-2.62 |
-2.38 |
0.14 |
-1.51 |
-5.06 |
-5.94 |
-37.57 |
0 |
| EPS |
-4.15 |
-3.71 |
0.76 |
-2.13 |
-1.73 |
-1.43 |
-1.25 |
-0.73 |
| EPS Diluted |
-4.15 |
-3.71 |
0.71 |
-2.13 |
-1.73 |
-1.43 |
-1.25 |
-0.73 |
| Weighted Average Shares
Out |
$74.00 M
|
$72.00 M
|
$69.35 M
|
$54.79 M
|
$43.83 M
|
$34.62 M
|
$42.55 M
|
$24.55 M
|
| Weighted Average Shares
Out Diluted |
$74.00 M
|
$72.00 M
|
$73.97 M
|
$54.79 M
|
$43.83 M
|
$34.62 M
|
$42.55 M
|
$24.55 M
|
| Link |
|
|
|
|
|
|
|
|
